Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma.
Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma.
复制标题
DOI：
10.1186/s13000-015-0401-2
复制
发表时间：
2015-09-17
影响因子：
2.6
通讯作者：
Li L
中科院分区：
文献类型：
--
作者：
Li Z;Jia M;Wu X;Cui J;Pan A;Li L
Trps1基因是加塔转录因子家族成员之一，在肿瘤的发生、发展中具有重要作用。然而，关于其在人骨肉瘤发生发展中的作用及其预后意义的研究却很少。采用免疫组化法检测Trps1的表达，CD31阳性内皮细胞计数法检测MVD，计算微血管数量。在接受研究的74例病例中，Trps1阳性病例为24例。与MVD显著相关（P = 0.008）。Trps1阳性组较阴性组有更多的远处转移（P = 0.013）和更高的Enneking分期（P = 0.017）。单因素分析显示，远处转移、MVD和Trps1表达与低3年总生存率和低无瘤生存率相关（分别为P = 0.003和P = 0.012）。多因素分析显示，Trps 1和远处转移仍是影响患者生存率的重要因素（P < 0.05）。Trps1在骨肉瘤的血管生成、转移和临床手术分期中起重要作用。Trps1可能是一个新的有前途的预后标志物和治疗靶点，靶向Trps1分子的抗血管生成治疗可能会改善骨肉瘤患者的预后和长期生存。
Trichorhinophalangeal syndrome 1 (Trps1) gene is a member of GATA transcription factor family and has an important function in tumorigenesis and progression. However, there are rare studies on its roles in carcinogenesis and prognostic significance in human osteosarcoma. The expression of Trps1 was detected by immunohistochemistry, and MVD was evaluated to determine the amounts of microvessels by counting CD31-positive endothelial cells. Of the 74 cases that underwent study, Trps1-positive cases were 24. And it was associated with MVD significantly (P = 0.008). The data also exhibited more cases of remote metastasis (P = 0.013) and higher Enneking stage (P = 0.017) in Trps1-positive group compared to Trps1-negative group. Univariate analysis revealed that distant metastasis, MVD and Trps1 expression were associated with a lower 3-year overall survival rate and disease-free survival rate (P = 0.003, and P = 0.012 respectively). Furthermore, Trps1 and distant metastasis retained their significant prognostic effects on patients survival rate by multivariate analysis (P < 0.05). Trps1 plays a crucial role in osteosarcoma angiogenesis, metastasis and clinical surgical stage. Trps1 can be a novel promising prognostic marker and therapeutic target, and antiangiogenic therapy which targets Trps1 molecule in patients with osteosarcoma may lead to improved prognosis and longer-term survival.